Study #2017-0201
Phase II Trial of Nivolumab plus Ipilimumab in Patients with Renal Medullary Carcinoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Ipilimumab, Nivolumab
Description
This phase II trial studies how well nivolumab and ipilimumab work in treating patients with kidney cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Kidney Medullary Carcinoma, Loss of INI 1 Protein Expression, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Study phase:
Phase II
Physician name:
Pavlos Msaouel
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.